http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Monopar Initiates Open-Label Phase 1b Clinical Trial Evaluating Camsirubicin in Patients with Advanced Soft Tissue Sarcoma
-
Monopar Initiates Open-Label Phase 1b Clinical Trial Evaluating Camsirubicin in Patients with Advanced Soft Tissue Sarcoma
-
Monopar Expands Phase 2b/3 VOICE Clinical Trial to Europe
-
Monopar Expands Phase 2b/3 VOICE Clinical Trial to Europe
-
Monopar Therapeutics to Present at Upcoming Investor Conferences in September
-
Monopar Therapeutics to Present at Upcoming Investor Conferences in September
-
Monopar Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Updates
-
Monopar Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Updates
-
Monopar Reaches Target Number of Clinical Sites in Phase 2b Portion of 2b/3 Validive® VOICE Trial
-
Monopar Reaches Target Number of Clinical Sites in Phase 2b Portion of 2b/3 Validive® VOICE Trial
-
Monopar Therapeutics (MNPR) Announces FDA Clearance to Proceed with Camsirubicin Clinical Trial Targeting Advanced Soft Tissue Sarcoma
-
Monopar Announces FDA Clearance to Proceed with Camsirubicin Clinical Trial Targeting Advanced Soft Tissue Sarcoma
-
Monopar Announces FDA Clearance to Proceed with Camsirubicin Clinical Trial Targeting Advanced Soft Tissue Sarcoma
-
Monopar Therapeutics (MNPR) Appoints Octávio Costa, MD, as Chief Medical Officer
-
Monopar Appoints Octávio Costa, MD, as Chief Medical Officer
-
Monopar Appoints Octávio Costa, MD, as Chief Medical Officer
-
Monopar Therapeutics (MNPR) to Present Results from Analysis of Oropharyngeal Cancer Patients in Completed Phase 2 Validive® Trial at MASCC/ISOO
-
Monopar to Present Results from Analysis of Oropharyngeal Cancer Patients in Completed Phase 2 Validive® Trial at MASCC/ISOO
-
Monopar to Present Results from Analysis of Oropharyngeal Cancer Patients in Completed Phase 2 Validive® Trial at MASCC/ISOO
-
Monopar Therapeutics (MNPR) Announces New Drug Candidate, MNPR-202, and Enters into Collaboration Agreement with the National University of Singapore for Preclinical Evaluation in Cancer
-
Monopar Announces New Drug Candidate, MNPR-202, and Enters into Collaboration Agreement with the National University of Singapore for Preclinical Evaluation in Cancer
-
Monopar Announces New Drug Candidate, MNPR-202, and Enters into Collaboration Agreement with the National University of Singapore for Preclinical Evaluation in Cancer
-
Monopar Therapeutics (MNPR) Appoints Andrew Cittadine as its COO
-
Monopar Therapeutics Expands Leadership Team with Appointment of Andrew Cittadine as Chief Operating Officer
-
Monopar Therapeutics Expands Leadership Team with Appointment of Andrew Cittadine as Chief Operating Officer
-
Monopar Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Updates
-
Monopar Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Updates
-
Monopar Therapeutics' (MNPR) uPA Antibody Fragment Radiotracer Shows Potential for PET Imaging of Breast Cancer in Preclinical Study
-
Monopar’s uPA Antibody Fragment Radiotracer Shows Potential for PET Imaging of Breast Cancer in Preclinical Study
-
Monopar’s uPA Antibody Fragment Radiotracer Shows Potential for PET Imaging of Breast Cancer in Preclinical Study
-
Monopar Therapeutics Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Business Updates
-
Monopar Therapeutics Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Business Updates
-
Monopar Therapeutics to Present at Upcoming Investor Conferences
-
Monopar Therapeutics to Present at Upcoming Investor Conferences
-
Monopar Expands Clinical Team with Appointment of Laura Kelly as Director of Clinical Operations
-
Monopar Expands Clinical Team with Appointment of Laura Kelly as Director of Clinical Operations
-
Monopar Announces First Patient Dosed in its Phase 2b/3 VOICE Trial Evaluating Validive® for the Prevention of Chemoradiotherapy-Induced Severe Oral Mucositis (SOM) in Oropharyngeal Cancer (OPC)
-
Monopar Announces First Patient Dosed in its Phase 2b/3 VOICE Trial Evaluating Validive® for the Prevention of Chemoradiotherapy-Induced Severe Oral Mucositis (SOM) in Oropharyngeal Cancer (OPC)
-
Monopar Therapeutics (MNPR) Announces Publication Demonstrating Potential Utility of MNPR-101 as an Imaging Agent to Improve Surgical Outcomes in Bladder Cancer
-
Monopar Announces Publication Demonstrating Potential Utility of MNPR-101 as an Imaging Agent to Improve Surgical Outcomes in Bladder Cancer
-
Monopar Announces Publication Demonstrating Potential Utility of MNPR-101 as an Imaging Agent to Improve Surgical Outcomes in Bladder Cancer
-
Monopar Therapeutics (MNPR) Announces Issuance of U.S. Patent Covering Compositions of Matter for a Novel Family of Camsirubicin Analogs
-
Monopar Announces Issuance of U.S. Patent Covering Compositions of Matter for a Novel Family of Camsirubicin Analogs
-
Monopar Announces Issuance of U.S. Patent Covering Compositions of Matter for a Novel Family of Camsirubicin Analogs
-
Monopar Therapeutics (MNPR) and NorthStar Announce Selection of uPRIT Candidate for Potential Treatment of Severe COVID-19
-
Monopar and NorthStar Announce Selection of uPRIT Candidate for Potential Treatment of Severe COVID-19
-
Monopar and NorthStar Announce Selection of uPRIT Candidate for Potential Treatment of Severe COVID-19
-
Monopar Announces Initiation of its Phase 2b/3 (VOICE) Trial to Evaluate Validive® for the Prevention of Chemoradiotherapy-Induced Severe Oral Mucositis (SOM) in Oropharyngeal Cancer (OPC)
-
Monopar Announces Initiation of its Phase 2b/3 (VOICE) Trial to Evaluate Validive® for the Prevention of Chemoradiotherapy-Induced Severe Oral Mucositis (SOM) in Oropharyngeal Cancer (OPC)
-
Monopar Therapeutics Reports Third Quarter 2020 Financial Results and Business Update
